Free from Publisher

Aspirin for primary prevention of CVD in CKD: where do we stand?

H Gallagher, M Lown, A Fuat, P Roderick - British Journal of General …, 2019 - bjgp.org
“CKD substantially increases the risk of CV events, with a graded relationship between
advancing stages of CKD and rates of fatal and non-fatal MI and the probablity of death …
被引用次数：5 相关文章

[引用][C] Aspirin for primary prevention of CVD in CKD: where do we stand?

HG Gallagher, M Lown, A Fuat… - British Journal of …, 2019 - eprints.soton.ac.uk
Aspirin for primary prevention of CVD in CKD: where do we stand? - ePrints Soton The
University of Southampton Courses University life Research Business Global About Visit …
[HTML] nih.gov

[HTML][HTML] Aspirin for primary prevention of CVD in CKD: where do we stand?

H Gallagher, M Lown, A Fuat… - The British Journal of …, 2019 - ncbi.nlm.nih.gov
“CKD substantially increases the risk of CV events, with a graded relationship between
advancing stages of CKD and rates of fatal and non-fatal MI and the probablity of death …

Aspirin for primary prevention of CVD in CKD: where do we stand?

H Gallagher, M Lown, A Fuat… - The British Journal of …, 2019 - europepmc.org
“CKD substantially increases the risk of CV events, with a graded relationship between
advancing stages of CKD and rates of fatal and non-fatal MI and the probablity of death …

[引用][C] Aspirin for primary prevention of CVD in CKD: where do we stand?

H Gallagher, M Lown, A Fuat… - The British journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Aspirin for primary prevention of CVD in CKD: where do we stand? Aspirin for primary
prevention of CVD in CKD: where do we stand? Br J Gen Pract. 2019 Nov 28;69(689):590-591 …